ELIAS Animal Health CEO, Tammie Wahaus, was the featured guest on the Fuzzybutts & Friends podcast. Hosted by Luke Robinson, founder of the PuppyUp Foundation, the podcast explores how the ELIAS Cancer Immunotherapy (ECI®) works against bone cancer in dogs, as well as how ELIAS is committed to developing more immunotherapies for pets with cancer. Check out the episode below! Learn more about the PuppyUp Foundation here. Watch more episodes of the Fuzzybutts & Friends podcast here.
Immunotherapy is increasingly becoming an important tool in the oncologist’s arsenal to improve clinical outcomes for both human and veterinary patients alike. Studies have shown that immunotherapies can produce durable responses in some patients, both human and companion animals. The power of combining immuno-oncology approaches such as adoptive cell therapies, oncolytic viruses, and checkpoint inhibitors, among others, has the potential to significantly increase the number of patients that become long term survivors. The article, "The future of canine cancer treatment" discusses the research ELIAS Animal Health is doing to evaluate how to improve patient response rates with these combination approaches. Read the full article at Veterinary Practice News online.
An Entrepreneur’s Journey | It Takes a Village: Understanding the Critical Roles Played by the Care Team Treating Canine Cancer Patients
We’re mid-way through An Entrepreneur’s Journey, a 3-part series that highlights the innovation, people, and opportunities that have been part of my ELIAS journey. Last week, I focused on solving a problem: treating dogs with cancer using methods that lengthened and improved their quality of life. This segment is dedicated to the people who are part of the solution. The family veterinarian plays an important role in a pet’s life and in the lives of the family who loves them, similar to that of a primary care doctor in the human realm. Through regular check-ups, the family veterinarian keeps the dog healthy. When he or she suspects something is wrong, they assess the issue and connect the pet and owners to a specialist if necessary. When a dog is diagnosed with cancer, it starts a process of care. The initial point of contact is often the family veterinarian, who diagnoses [...]
In this final installment of the Canine Cancer Continuum, we talk about immunotherapy - what it is, how it works, and how it can help in the fight against cancer. (Check out Part 1 and Part 2.) “Without an immune system, we would have no way to fight harmful things that enter our body from the outside or harmful changes that occur inside our body. The main tasks of the body’s immune system are: to fight disease-causing germs (pathogens) like bacteria, viruses, parasites or fungi, and to remove them from the body, to recognize and neutralize harmful substances from the environment, and to fight disease-causing changes in the body, such as cancer cells.” (National Institutes of Health) In a nutshell, our immune systems are powerful mechanisms designed to protect us and keep us healthy. They work 24/7 to fight off external threats, like viruses and environmental stressors, and internal threats, like stresses to normal [...]
We’re halfway through a series exploring canine cancer. Last week, we discussed the prevalence of dog cancer, and today we will explore the connection between it and human cancer. Human cancer research is extensive. Almost anyone I encounter has either battled cancer themselves or has journeyed that path with someone close to them. Many people are surprised to learn that one in four dogs are diagnosed with cancer and that it’s the leading cause of death in canines. ELIAS Animal Health applies the advancements in human immunotherapy to dogs. They’re good models. From a scientific perspective, we are able to gather data more quickly than in human research because dogs have a shorter lifespan and cancer progresses more quickly in them. From a “we love our furry friends” perspective, we want to bring needed therapies into the veterinary marketplace that help people. ELIAS Cancer Therapies Are Being Simultaneously Developed for Humans [...]
We’re embarking on a 3-part series that explores dog cancer, how our research and progress can be applied to humans, what immunotherapy is, and why it can be so effective. “Cancer is the leading cause of death in dogs and as a rank order, higher than people…” - Dr. Doug Thamm Dogs live in the same environments as humans, exposed to the carcinogens that their owners are. It’s not surprising, then, that one in four dogs is diagnosed with cancer, and it’s the leading cause of death in pets beyond middle age (Veterinary Cancer Society). Dogs experience cancer at rates that are comparable to or exceed those in humans. Canine cancer has primarily been treated the same way for decades - with chemotherapy. Dr. Carolyn Henry, Dean of the University of Missouri College of Veterinary Medicine, has said she is “frustrated by the fact that we don’t see many new therapies coming [...]
Olathe, Kan., June 6, 2019 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, and BodeVet, a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion and regenerative medicine, have announced a joint effort to significantly expand the availability of ELIAS’ ECI® treatment for canine cancer via the mobile apheresis capabilities of BodeVet. Apheresis is a processing procedure that separates blood into different components and, in this case, yields the T cells critical to the ELIAS treatment protocol. Currently, there are twelve locations offering apheresis for pets. BodeVet offers a mobile service that will enable veterinary oncologists in most major cities in the United States to incorporate ECI® into their specialty hospital portfolio of oncology services, expanding beyond chemotherapy and radiation. Working together, ELIAS and BodeVet are committed to promoting animal health and welfare by developing [...]
Olathe, Kan., May 15, 2019 – ELIAS Animal Health, a Kansas City company dedicated to improving the treatment options for companion animals diagnosed with cancer, will be featured on Worldwide Business with kathy ireland®. Distributed internationally as sponsored content, you can view a highlight video below. The full interview will air on the following channels: Americas: Fox Business Network May 19, 2019, 5:30 p.m. EST Europe & Africa: Bloomberg EMEA Saturday, May 18, 2019, 7:30 p.m. GMT Asia: Bloomberg Asia Sunday, May 19, 2019, 10:30 a.m. D.F. and 3:00 p.m. HKT
The University of Missouri recently shared progress on their work in helping advance ELIAS Animal Health’s treatment for bone cancer in dogs. The canine immunotherapy treatment is now available at MU, as well as at other universities and specialty hospitals across the country. Dr. Jeff Bryan, director of the MU's Comparative Oncology and Epigenetics Laboratory and principal investigator of the clinical trial, said of the treatment, “It’s the first time that dogs with osteosarcoma have experienced prolonged survival without receiving chemotherapy, which is really exciting.” Read the full announcement.
Olathe, Kan., Oct. 25, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ECI® (ELIAS Cancer Immunotherapy) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days1). These results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field safety and efficacy study in early 2019. “We are very encouraged by our osteosarcoma clinical trial results as we move towards commercialization of ECI® for the veterinary community, while continuing to explore our platform technology in other cancers such as lymphoma,” said Noe Reyes, D.V.M., ELIAS medical director. The trial [...]